Loading...
Current status of biosimilars in the treatment of inflammatory bowel diseases
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden...
Na minha lista:
| Udgivet i: | Intest Res |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Korean Association for the Study of Intestinal Diseases
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4754516/ https://ncbi.nlm.nih.gov/pubmed/26884730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2016.14.1.15 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|